Is Kodiak Sciences Inc. (KOD) a Buy, Sell, or Hold?
Kodiak Sciences Inc.
NASDAQ:KOD
$42.42 USD
-$0.84 (-1.94%)
- Volume
- 688.92K
- Average Volume
- 757.33K
- Market Capitalization
- $2.25B
- P/E Ratio
- -10.17
- Dividend Yield
- 0.00%
- Price Target
- $59.50
- Year High
- $47.84
- Year Low
- $4.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.54
| Source | Headline |
|---|---|
|
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development. seekingalpha.com - 2026-06-16 12:09:59 |
|
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance. fool.com - 2026-06-09 19:44:25 |
|
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet. zacks.com - 2026-06-04 12:07:09 |
|
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D. prnewswire.com - 2026-05-28 18:09:00 |
|
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials. fool.com - 2026-05-17 15:57:13 |
|
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans. zacks.com - 2026-05-08 13:41:20 |
|
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. prnewswire.com - 2026-05-07 16:00:00 |
|
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. prnewswire.com - 2026-05-01 00:23:00 |
|
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? zacks.com - 2026-04-30 12:31:29 |
